Provided by Tiger Fintech (Singapore) Pte. Ltd.

Amgen

278.40
+4.721.72%
Post-market: 277.01-1.3900-0.50%16:49 EDT
Volume:2.08M
Turnover:575.60M
Market Cap:149.68B
PE:36.83
High:278.73
Open:275.70
Low:274.49
Close:273.68
Loading ...

NVO & LLY Shares Down on Exclusion of Obesity Drugs From Medicare

Zacks
·
07 Apr

This Type of Cholesterol Is a Risk Factor for Heart Disease. Emerging Drugs from Lilly and Amgen Could Treat It. -- Barrons.com

Dow Jones
·
07 Apr

Amgen (NasdaqGS:AMGN) Gains FDA Approval For UPLIZNA In Treating IgG4-Related Disease

Simply Wall St.
·
05 Apr

AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication

Zacks
·
05 Apr

The Dow Needs A Refresh. These New Members Could Make It Sing. -- Barrons.com

Dow Jones
·
05 Apr

Shares of Some U.S. Drugmakers Down After Trump Says Pharmaceutical Sector Is 'Under Review' for Tariffs

THOMSON REUTERS
·
04 Apr

Amgen Says Uplizna Wins US FDA Approval for IgG4-related Disease

MT Newswires Live
·
04 Apr

BUZZ-US drugmakers fall after Trump's new tariff warnings

Reuters
·
04 Apr

11 Stocks to Buy After the Biotech Bloodbath -- Barrons.com

Dow Jones
·
04 Apr

BRIEF-Amgen Uplizna Wholesale Acquisition Cost Or U.S. List Price Is $140,248.50 Per Dose (3 Vials)

Reuters
·
04 Apr

Amgen Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily Gains

Dow Jones
·
04 Apr

Amgen: Uplizna Wholesale Acquisition Cost or U.S. List Price Is $140,248.50 per Dose (3 Vials)

THOMSON REUTERS
·
04 Apr

FDA Approves Second Indication for Amgen's Immune System Treatment Uplizna

Dow Jones
·
04 Apr

Amgen announces FDA approval of Uplizna

TIPRANKS
·
04 Apr

Uplizna® (Inebilizumab-Cdon) Is NOW the First and Only FDA-Approved Treatment for Igg4-Related Disease

THOMSON REUTERS
·
04 Apr

UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE

PR Newswire
·
04 Apr

US FDA approves Amgen's Uplizna as first treatment for rare immune disorder

Reuters
·
04 Apr

US FDA approves expanded use of Amgen's rare disease drug

Reuters
·
04 Apr

BRIEF-FDA Approves Amgen's Uplizna For Treatment Of Immunoglobulin G4-Related Disease In Adult Patients

Reuters
·
04 Apr

FDA Approves Amgen's Uplizna for Treatment of Immunoglobulin G4-Related Disease in Adult Patients - Website

THOMSON REUTERS
·
04 Apr